ArticleAnnals of global health2023
Engaging with the Private Sector for Noncommunicable Disease Prevention and Control: Is it Possible to Create "Shared Value?"
Article in Annals of global health, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Linking Health Financing to Oral Health Coverage and Disease Burden in SEARO Countries: A Cross-Sectional Analysis of Country Level Data.The International journal of health planning and management · 2026Article
- Dietary acid load and its association with all-cause mortality, cardiovascular mortality, and events.Scientific reports · 2025Article
- Private sector engagement strategies with implications for NCD prevention and control: focus on ten international organisations.Global health research and policy · 2025Article
- Managing engagement among public, private and civil society actors participating in NewTools: a research partnership on food profiling.Public health nutrition · 2025Article
- [Reflections on implementing population-based measures for the prevention of non-communicable diseases].Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz · 2025Article
- Toward Monitoring and Addressing the Commercial Determinants of Health: Where Can We Go From Here?The Milbank quarterly · 2025Article
- Reflections on Corporate Political Activity Taxonomies in the Context of Non-communicable Diseases and Mental Health Comment on "Corporate Political Activity: Taxonomies and Model of Corporate Influence on Public Policy".International journal of health policy and management · 2025Article
- Characterizing stakeholders in cancer primary prevention in European countries: an exploration of challenges and opportunities using a penta-helix framework.Frontiers in public health · 2025Article
- Alarming Rise of Obesity: The 4Global heart · 2025Article
- Cost of Care for Non-communicable Diseases: Which Types of Healthcare Providers are the Most Economical in India's Chhattisgarh State?PharmacoEconomics - open · 2024Article
- Multisectoral action to address noncommunicable diseases: lessons from three country case studies.Frontiers in public health · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Noncommunicable diseases (NCDs) are the leading cause of premature mortality worldwide. Corporate interests are sometimes well-aligned with public health, but profiteering from the consumption of products that are known to be the major contributors to the noncommunicable disease burden undermines public health. This paper describes the key industry actors shaping the NCD landscape; highlights the unhealthy commodities' impact on health and the growing burden of NCDs; and outlines challenges and opportunities to reduce exposure to those risk factors. Corporations deploy a wide array of strategies to maximize profits at the expense of health, including sophisticated marketing techniques, interference in the policy-making process, opposition and distortion of research and evidence, and whitewashing of health-harming activities through corporate social responsibility initiatives. There can be no shared value for industries that sell goods that harm health irrespective of consumption patterns (such as tobacco and likely alcohol), so government actions such as regulation and legislation are the only viable policy instruments. Where shared value is possible (for example, with the food industry), industry engagement can potentially realign corporate interests with the public health interest for mutual benefit. Deliberate, careful, and nuanced approaches to engagement are required.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.